Clinical trial (n=36) shows the ability of gammaCore (nVNS) to significantly improve the recall of a foreign language compared to sham while simultaneously showing improved focus and decreased fatigue in study participants ROCKAWAY, N.J. , April 24, 2023 (GLOBE NEWSWIRE) -- electroCore,
ROCKAWAY, N.J. , April 19, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2023 , after the close of the market on Wednesday, May 3, 2023 .
Record revenue of approximately $2.8M expected for the three months ended March 31, 2023 ; 46% increase over first quarter of 2022 Revenue in first full quarter of Truvaga sales of approximately $147,000 expected ROCKAWAY, N.J. , April 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc.
electroCore Granted Three New U.S. Patents ROCKAWAY, N.J. , April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and
ROCKAWAY, N.J. , April 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Teijin Limited ( Teijin ), a global conglomerate based in Japan offering advanced solutions in healthcare,
ROCKAWAY, N.J. , April 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a license to import, distribute and market gammaCore Sapphire™, non-invasive vagus nerve stimulator
ROCKAWAY, N.J. , April 04, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase by clinicians
Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function post injury ROCKAWAY, N.J. , March 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company,
ROCKAWAY, N.J. , March 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of a Truvaga TM focus group study conducted earlier this year.
ROCKAWAY, N.J. , March 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it does not have direct exposure to Silicon Valley Bank , Silvergate Bank , or Signature Bank.